Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response

Infectious Disease Clinics of North America

Volumn 20, Issue 1, 2006, Pages 115-135

  Sethi, Amrita ^a   Shiffman, Mitchell L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ALPHA INTERFERON; AMANTADINE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; COLCHICINE; CONSENSUS INTERFERON; CPG 10101; IDN 1566; INTERFERON; ISIS 14803; MAXIMINE; NM 283; PEGINTERFERON; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SCH 503034; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRAMADINE; VX 950;

ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FLU LIKE SYNDROME; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRRITABILITY; LIVER CIRRHOSIS; LIVER FIBROSIS; MENTAL DISEASE; NEUTROPENIA; NONHUMAN; RELAPSE; REVIEW; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT FAILURE;

EID: 33644775538     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.01.002     Document Type: Review

References (90)

1. J.H. Hoofnagle, K.D. Mullen, and B. Jones Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon N Engl J Med 315 1986 1575 1578
2. B.J. Thomson, M. Doran, and A.M.L. Lever Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy Lancet 1 1987 539 541
3. T. Poynard, P. Bedossa, and M. Chevallier A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis N Engl J Med 332 1995 1457 1462
4. J.G. McHutchinson, S. Gordon, and E.R. Schiff Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 339 1998 1485 1492
5. T. Poynard, P. Marcellin, and S.S. Lee Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
6. K.R. Reddy, T.L. Wright, and P.J. Pockros Efficacy and safety of pegylated (40-KD) interferon α-2a compared with interferon α-2a in non-cirrhotic patients with chronic hepatitis C Hepatology 33 2001 433 438
7. S. Zeuzem, S.V. Feinman, and J. Rasenack Peginterferon-alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666 1672
8. E.J. Heathcote, M.L. Shiffman, and W.G. Cooksley Peginterferon Alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
9. K.L. Lindsay, C. Trepo, and T. Heintges A randomized, double-blind trial comparing peginterferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
10. M.P. Manns, J.G. McHutchinson, and S.C. Gordon Peginterferon-alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 2001 958 965
11. M.W. Fried, M.L. Shiffman, and K.R. Reddy Combination of peginterferon alfa-2a (40 kd) plus ribavirin in patients with chronic hepatitis C vims infection N Engl J Med 347 2002 975 982
12. S.J. Hadziyannis, H. Sette Jr., and T.R. Morgan Peginterferon-alfa 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
13. M.L. Shiffman, A.M. Di Bisceglie, and K.L. Lindsay Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023
14. I.M. Jacobsen, F. Ahmed, and M.W. Russo Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results Gastroenterology 124 Suppl 1 2003 A-714
15. S.K. Herrine, R. Brown Jr., and S. Esposito Efficacy and safety of peginterferon alfa-2a combination therapies in patients who relapsed on rebetron therapy Hepatology 36 Suppl 1 2002 358A
16. E.L. Krawitt, S.D. Lidofsky, and N. Ferrentino Efficacy of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C previously unresponsive to interferon-based therapy Hepatology 36 Suppl 1 2002 359A
17. A. Ferreira-Gonzalez, and M.L. Shiffman Use of diagnostic testing for managing hepatitis C virus infection Semin Liver Dis 24 Suppl 2 2004 9 18
18. K.L. Lindsay Therapy of hepatitis C: overview Hepatology 27 Suppl 1 1997 71S 77S
19. K.L. Lindsay Introduction to therapy of hepatitis C Hepatology 36 Suppl 1 2002 S114 S120
20. G.L. Davis, J.B. Wong, and J.G. McHutchison Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
21. J. Saldanha, N. Lelie, and A. Heath Establishment of the first international standard for nucleic acid amplification technology assays for HCV RNA. WHO collaborative study group Vox Sang 76 1999 149 158
22. M.L. Shiffman, A. Ferreira-Gonzalez, and K.R. Reddy Comparison of three commercially available assays for HCV RNA using the international unit standard: implications for management of patients with chronic hepatitis C virus infection in clinical practice Am J Gastroenterol 98 2003 1159 1166
23. J.C. Anderson, J. Simonetti, and D.G. Fisher Comparison of different HCV viral load and genotyping assays J Clin Viral 28 2003 27 37
24. F.S. Nolte, M.W. Fried, and M.L. Shiffman Prospective multicenter clinical evaluation of AMPL1COR and COBAS AMPLICOR hepatitis C virus tests J Clin Microbiol 39 2001 4005 4012
25. C. Morishima, and D.R. Gretch Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy Clin Liver Dis 3 1999 717 740
26. G.L. Davis Monitoring of viral levels during therapy of hepatitis C Hepatology 36 Suppl 1 2002 S145 S151
27. M.L. Shiffman Side effects of medical therapy for chronic hepatitis C Ann Hepatol 3 2004 5 10
28. J.G. McHutchison, M. Manns, and K. Patel Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
29. S. Hadziyannis, H. Cheinquer, and T. Morgan Peginterferon alfa-2a in combination with ribavirin: efficacy and safety results from a phase III randomized, double-blind, multicenter trial examining effect of duration of treatment and ribavirin dose J Hepatol 36 Supp 1 2002 3
30. M.L. Shiffman, T.R. Morgan, and M.G. Ghany The impact of peginterferon and ribavirin dosing on sustained virologic response in patients with chronic hepatitis C virus undergoing retreatment in the HALT-C trial. HALT-C trial group Hepatology 40 Suppl 1 2004 314A
31. L. De Franceschi, G. Fattovich, and F. Turrini Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage Hepatology 31 2000 997 1004
32. M.L. Shiffman, C.M. Hermann, and R.K. Sterling A randomized, controlled trial to determine if continuing ribavirin as monotherapy in patients who responded to interferon/ribavirin combination therapy will enhance sustained virologic response J Infect Dis 184 2001 405 409
33. W.C. Maddrey Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients Semin Liver Dis 19 Suppl l 1999 67 75
34. M. Nichols, and M. Kugelmas Reasons for discontinuation of treatment of chronic hepatitis C: an interim analysis of the Frontier trial Gastroenterology 124 Suppl 1 2003 A703
35. D.T. Dieterich, R. Wasserman, and N. Brau Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa Am J Gastroenterol 98 2003 2491 2499
36. N.H. Afdhal, D.T. Dieterich, and P.J. Pockros Correction of anemia with epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind study Gastroenterology 126 2004 1302 1311
37. P.J. Pockros, M.L. Shiffman, and E.R. Schiff Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
38. F. Ahmed, I.M. Jacobson, and R.S. Brown Jr. Neutropenia and infections in the WIN-R trial Gastroenterology 124 Suppl 1 2003
39. A.L. Boks, E.J. Brommer, and S.W. Schalm Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage Hepatology 6 1986 79 86
40. P. Hauser Neuropsychiatric side effects of HCV therapy and their treatment focus on IFN alpha-induced depression Gastroenterol Clin North Am 33 Suppl 1 2004 S35 S50
41. C. Maddock, A. Baita, and M.G. Orru Psychopharmacologic treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biologic mechanisms J Psychopharmacol 18 2004 41 46
42. E.R. Schiff, and N. Ozden Hepatitis C and alcohol Alcohol Res Health 27 2003 232 239
43. M.G. Peters, and N.A. Terrault Alcohol use and hepatitis C Hepatology 36 2002 S220 S225
44. C. Loguercio, M. Di Pierro, and M.P. Di Marino Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects Alcohol 35 2000 296 301
45. B.R. Edlin Prevention and treatment of hepatitis C in injection drug users Hepatology 36 Suppl 1 2002 S210 S219
46. D.L. Sylvestre, and B.J. Clements The impact of negative prognostic factors on hepatitis C treatment outcomes in recovering injection drug users Hepatology 36 2002 223A
47. J.G. McHutchison, and K. Patel Future therapy of hepatitis C Hepatology 36 2002 S245 S252
48. H. Hinrichsen, Y. Benhamou, and H. Wedemeyer Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients Gastroenterology 127 2004 1347 1355
49. C. O'Brien, E. Godofsky, and M. Rodriquez-Torres Randomized trial of valopicitabine (NM283) alone or with peg-interferon vs. retreatment with peg-interferon plus ribavirin in hepatitis C patients with previous non-response PEGIFN/RBV: first interim results [abstract #95] Hepatology 42 2005 234A
50. H.W. Reesink, S. Zeuzem, and C.J. Weegink Final results of a phase 1b, multiple dose study of VX-950, a hepatitis C virus protease inhibitor [abstract #96] Hepatology 42 2005 234A 235A
51. S. Zeuzem, C. Sarrazin, and F. Wagner Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype 1 peg-intron non-responders: Phase 1b results [abstract #201] Hepatology 42 2005 276A
52. E.J. Heathcote, E.B. Keeffe, and S.S. Lee Re-treatment of chronic hepatitis C with consensus interferon Hepatology 27 1998 1136 1143
53. S. Kaiser, H. Hass, and M. Gregor Successful retreatment of peginterferon nonresponders with chronic hepatitis C with high dose consensus interferon induction therapy Gastroenterology 124 Suppl 1 2003 A700
54. C. Leevy II, C. Chamers, and L. Blatt Comparison of African American and non-African American patient end of treatment response for PEG1FN alpha-2a and weight based ribavirin nonresponders retreated with 1FN alfacon-1 and weight based ribavirin Hepatology 40 Suppl 1 2004 240A
55. A.J. Muir, J.D. Bornstein, and P.G. Killenberg Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites N Engl J Med 350 2004 2265 2271
56. M. Diago, J. Crespo, and A. Oliveira Peginterferon alfa-2a and ribavirin in patients infected with HCV genotype 1 who failed to respond to interferon and ribavirin: final results of the Spanish high dose induction pilot trial Hepatology 40 Suppl 1 2004 389A
57. J.M. Sanchez-Tapias, M. Diago, and P. Escartin Hepatology 40 Suppl 1 2004 218A
58. Z.M. Younossi, and R.P. Perrillo The roles of amantadine, rimantadine, ursodeoxycholic acid and NSAIDs, alone or in combination with alfa interferons in the treatment of chronic hepatitis C Semin Liver Dis 19 1999 95 102
59. J.P. Smith Treatment of chronic hepatitis C with amantadine Dig Dis Sci 42 1997 1681 1687
60. B. Helbling, I. Stamenic, and F. Viani Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial Hepatology 35 2002 447 454
61. G. Teuber, M. Pascu, and T. Berg Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C JHepatol 39 2003 606 613
62. P.J. Thuluvath, A. Maheshwari, and J. Mehdi Randomized, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C Gut 53 2004 130 135
63. A. Mangia, G. Leandro, and B. Helbling Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials J Hepatol 40 2004 478 483
64. S. Fargion, M. Borzio, and O. Predabissi End of treatment and sustained response to peginterferon alfa-2a plus ribavirin and amantadine and to induction therapy with interferon alfa-2a plus ribavirin and amantadine in interferon/ribavirin nonresponders with chronic hepatitis C Hepatology 38 Suppl 1 2003 733A
65. N.S. Cantu, M. Davis, and N. Afdahl Triple therapy compared to standard pegylated interferon alfa-2b and weight based ribavirin for previous nonresponders and relapsers with chronic hepatitis C Hepatology 38 Suppl 1 2003 742A
66. M.L. Shiffman, C.M. Hermann, and E.B. Thompson Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C Hepatology 26 1997 780 785
67. M.L. Shiffman Histologic improvement in response to interferon therapy in chronic hepatitis C Viral Hepatitis Rev 5 1999 27 43
68. T. Poynard, J. McHutchison, and M. Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313
69. Y. Imai, S. Kawata, and S. Tamura Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 1998 94 99
70. H. Yoshida, Y. Arakawa, and M. Sata Interferon therapy prolonged life expectancy among chronic hepatitis C patients Gastroenterology 123 2002 483 491
71. G. Fattovich, G. Giustina, and F. Degos Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European concerted action on viral hepatitis J Hepatol 27 1977 201 205
72. M.L. Shiffman, C.M. Hofmann, and M.J. Contos A randomized, controlled trial of maintenance interferon for treatment of chronic hepatitis C non-responders Gastroenterology 117 1999 1164 1172
73. M. Yano, H. Kumada, and M. Kage The long term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
74. M.G. Ghany, D.E. Kleiner, and H. Alter Progression of fibrosis in chronic hepatitis C Gastroenterology 124 2003 97 104
75. W.M. Lee, J.L. Dienstag, and K.L. Lindsay Evolution of the HALT-C trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders Control Clin Trials 25 2004 472 492
76. N. Afdhal, B. Freilich, and R. Levine Colchicine versus Peg-Intron long term (CoPilot) trial: interm analysis of clinical outcomes at year 2 Hepatology 40 Suppl 1 2004 239A
77. J.H. Hoofnagle, M.G. Ghany, and D.E. Kleiner Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin Hepatology 38 2003 66 74
78. A.M. Di Bisceglie, H.S. Conjeevaram, and M.W. Fried Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 897 903
79. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINVIR and DOSVIRC groups Lancet 349 1997 825 832
80. N.H. Afdhal The natural history of hepatitis C Semin Liver Dis 24 Suppl 2 2004 3 8
81. K. Safdar, and E.R. Schiff Alcohol and hepatitis C Semin Liver Dis 24 2004 305 315
82. T.E. Wiley, M. McCarthy, and L. Breidi Impact of alcohol on the histological and clinical progression of hepatitis C infection Hepatology 28 1998 805 809
83. S. Ramesh, and A.J. Sanyal Hepatitis C and nonalcoholic fatty liver disease Semin Liver Dis 24 2004 399 413
84. Z.M. Younossi, A.J. McCullough, and J.P. Ong Obesity and non-alcoholic fatty liver disease in chronic hepatitis C J Clin Gastroenterol 38 2004 705 709
85. P. Haynes, S. Liangpunsakul, and N. Chalasani Nonalcoholic fatty liver disease in individuals with severe obesity Clin Liver Dis 8 2004 535 547
86. A. Lonardo, L.E. Adinolfi, and P. Loria Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease Gastroenterol 126 2004 586 597
87. G. Reiss, and E.B. Keeffe Review article: hepatitis vaccination in patients with chronic liver disease Aliment Pharmacol Ther 19 2004 715 727
88. D.B. Strader, T. Wright, and D.L. Thomas Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
89. S. Vento, T. Garofano, and C. Renzini Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C N Engl J Med 338 1998 286 290
90. R.K. Sterling, and M.S. Sulkowski Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection Semin Liver Dis 24 Suppl 2 2004 61 68